News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Adaptive Biotech Announces Translational Collaboration With NCI



7/26/2017 8:14:41 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs

Adaptive’s immunoSEQ® Platform to be Used for Immunosequencing-based Biomarker Discovery in NCI-sponsored Clinical Trials

SEATTLE--(BUSINESS WIRE)--Adaptive Biotechnologies, a pioneer in combining next-generation sequencing and expert bioinformatics to profile T-cell and B-cell receptors (TCRs and BCRs) of the adaptive immune system, today announced a translational collaboration with the Cancer Therapy Evaluation Program (CTEP) of the National Cancer Institute (NCI), part of the National Institutes of Health.

Under this collaboration, the Adaptive immunoSEQ Platform will be used to more broadly incorporate TCR and BCR sequencing into select NCI-sponsored clinical trials. The goal is to apply this Platform to accurately measure and track immune repertoire dynamics that may drive response to different cancer immunotherapies.

In line with NCI efforts to implement novel correlative strategies across select clinical trials and tumor types, expanding the use of immunosequencing by NCI investigators may help better understand and potentially predict response to novel immuno-modulatory agents. Both Adaptive and NCI/CTEP are committed to accelerating the clinical validation and utility of novel immune-based molecular biomarkers from tissue and/or blood of cancer patients to better inform treatment decisions.

We are delighted to announce our engagement with NCI,” said Chad Robins, chief executive officer and founder at Adaptive Biotechnologies. “It’s our goal to support NCI investigators by enriching their research and expertise in immune correlative data generation with Adaptive’s immunoSEQ Platform, and to help expedite the development of new immune molecular biomarkers that inform the next wave of novel therapies and rational combinations.”

About Adaptive Biotechnologies

Adaptive Biotechnologies is a pioneer in combining high-throughput sequencing and expert bioinformatics to profile T-cell and B-cell receptors. Adaptive is bringing the accuracy and sensitivity of its immunosequencing platform into laboratories around the world to drive groundbreaking research in cancer and other immune-mediated diseases. Adaptive also translates immunosequencing discoveries into clinical diagnostics and therapeutic development to improve patient care. For more information, please visit www.adaptivebiotech.com.

About the immunoSEQ Platform

Adaptive’s immunoSEQ Platform helps researchers make discoveries in areas such as oncology, autoimmune disorders, infectious diseases and basic immunology. The immunoSEQ Assays can identify millions of T- and B-cell receptors from a single sample in exquisite detail. Offered as a Service or Kit, immunoSEQ Assays provide quantitative, reproducible sequencing results along with access to powerful, easy-to-use analysis tools. The immunoSEQ Assays are for research use only and are not for use in diagnostic procedures.

Adaptive Biotechnologies
Beth Keshishian
917-912-7195
media@adaptivebiotech.com


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES